|Articles|June 22, 2009

FDA's Keith Webber on Setting Specifications

Author(s)BioPharm International Editors

FDA´s Keith Webber on Setting Specifications

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Related Content

Woman injects herself with the drug Ozempic anti-diabetes pen into her arm at home. Weight loss and decreased blood sugar, concept idea. injector dosing pen for subcutaneous injection | Image credit: © alones - © alones - stock.adobe.com

FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery

ByFeliza Mirasol

January 28th 2026

Antibody | Image credit: © Design Cells - © Design Cells - stock.adobe.com

FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma

ByFeliza Mirasol

January 28th 2026

Colorful chain of amino acids or bio molecules called proteins - 3d illustration | Image credit: © Christoph Burgstedt - © Christoph Burgstedt - stock.adobe.com

HanchorBio–WuXi Biologics Partnership Targets Fusion Protein Development Challenges

ByFeliza Mirasol

January 27th 2026

Businessman using magnifying glass to recruit people 3D rendering | Image Credit: © sdecoret - stock.adobe.com

Bio/pharma Manufacturing Professionals Are Staying Put Despite Growing Uncertainty

ByChristopher Cole

January 26th 2026

Doctor making injection to senior patient in clinic | Image credit: © InsideCreativeHouse - © InsideCreativeHouse - stock.adobe.com

GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older

ByFeliza Mirasol

January 26th 2026

FDA's Keith Webber on Setting Specifications

Newsletter

Related Content

FDA Priority Review of Subcutaneous Lecanemab Signals Shift in Alzheimer’s Treatment Delivery

FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma

HanchorBio–WuXi Biologics Partnership Targets Fusion Protein Development Challenges

Bio/pharma Manufacturing Professionals Are Staying Put Despite Growing Uncertainty

GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older

Trending on BioPharm International

HanchorBio–WuXi Biologics Partnership Targets Fusion Protein Development Challenges

GSK’s Arexvy Gains EU Approval for Adults Aged 18 Years and Older

FDA Fast Tracks Innovent’s Trispecific Antibody for Multiple Myeloma

Bio/pharma Manufacturing Professionals Are Staying Put Despite Growing Uncertainty

Subvisible Particulate Matter Testing